文献速递新发突发、热带与寄生虫病

规律剂量对乙酰氨基酚与不使用对乙酰氨基酚对诺氏疟原虫疟疾肾功能的影响(PACKNOW):一项随机对照试验

The Effect of Regularly Dosed Acetaminophen vs No Acetaminophen on Renal Function in Plasmodium knowlesi Malaria (PACKNOW): A Randomized, Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2022-01-01

PACKNOW为开放标签随机对照试验,在马来西亚≥5岁诺氏疟疾患者中比较对乙酰氨基酚(每6小时500或1000 mg,共72小时)与不用药对72小时肌酐变化的影响。2016-2018年共纳入396例,整体肌酐下降幅度两组无显著差异(对乙酰氨基酚组平均下降14.9% vs 对照组14.6%,P=.81)。结论:对乙酰氨基酚未改善整体队列肌酐,但可能改善重症诺氏疟疾及急性肾损伤合并溶血患者的肾功能。

要点

  • 整体队列中,对乙酰氨基酚组72小时肌酐平均下降14.9%,对照组下降14.6%,差异无统计学意义(P=.81)。
  • 重症疟疾患者中,对乙酰氨基酚组肌酐下降31.0%,对照组下降20.4%,差异无统计学意义(P=.12)。
  • 急性肾损伤合并溶血患者中,对乙酰氨基酚组肌酐下降34.5%,对照组下降25.9%,差异有统计学意义(P=.041)。

核心结论

  • 对乙酰氨基酚未改善整体诺氏疟疾队列的肌酐,但可能改善重症诺氏疟疾及急性肾损伤合并溶血患者的肾功能。

研究设计与样本

  • PACKNOW为开放标签随机对照试验,纳入马来西亚≥5岁任何严重程度的诺氏疟疾患者。
  • 对乙酰氨基酚组给予500 mg或1000 mg每6小时一次共72小时,对照组不使用对乙酰氨基酚。
  • 2016-2018年共随机分配396例(年龄12-96岁),对乙酰氨基酚组199例,对照组197例。
  • 主要终点为72小时肌酐变化;次要终点包括重症疟疾或急性肾损伤患者按溶血分层的肌酐纵向变化。

主要发现

  • 整体队列中,对乙酰氨基酚组肌酐平均下降14.9%(标准差18.1),对照组下降14.6%(标准差16.0),P=.81。
  • 重症疟疾患者中,对乙酰氨基酚组肌酐下降31.0%(标准差26.5),对照组下降20.4%(标准差21.5),P=.12。
  • 溶血患者中,对乙酰氨基酚组肌酐下降35.8%(标准差26.7),对照组下降19%(标准差16.6),P=.07。
  • 急性肾损伤患者整体未见差异;但在急性肾损伤合并溶血患者中,对乙酰氨基酚组肌酐下降34.5%(标准差20.7),对照组下降25.9%(标准差15.8),P=.041。
  • 混合效应模型显示,在重症疟疾以及急性肾损伤合并溶血患者中,对乙酰氨基酚在72小时(P=.041和P=.027)和1周(P=.002和P=.002)均显示获益。

关键数值与推荐

  • 主要终点72小时肌酐变化:对乙酰氨基酚组平均下降14.9% vs 对照组14.6%(P=.81)。
  • 重症疟疾肌酐变化:对乙酰氨基酚组下降31.0% vs 对照组20.4%(P=.12)。
  • 急性肾损伤合并溶血肌酐变化:对乙酰氨基酚组下降34.5% vs 对照组25.9%(P=.041)。
  • 混合效应模型:重症疟疾72小时P=.041、1周P=.002;急性肾损伤合并溶血72小时P=.027、1周P=.002。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acetaminophen inhibits cell-free hemoglobin-induced lipid peroxidation and improves renal function in severe falciparum malaria but has not been evaluated in other infections with prominent hemolysis, including Plasmodium knowlesi malaria. METHODS: PACKNOW was an open-label, randomized, controlled trial of acetaminophen (500 mg or 1000 mg every 6 hours for 72 hours) vs no acetaminophen in Malaysian patients aged ≥5 years with knowlesi malaria of any severity. The primary end point was change in creatinine at 72 hours. Secondary end points included longitudinal changes in creatinine in patients with severe malaria or acute kidney injury (AKI), stratified by hemolysis. RESULTS: During 2016-2018, 396 patients (aged 12-96 years) were randomized to acetaminophen (n = 199) or no acetaminophen (n = 197). Overall, creatinine fell by a mean (standard deviation) 14.9% (18.1) in the acetaminophen arm vs 14.6% (16.0) in the control arm (P = .81). In severe disease, creatinine fell by 31.0% (26.5) in the acetaminophen arm vs 20.4% (21.5) in the control arm (P = .12), and in those with hemolysis by 35.8% (26.7) and 19% (16.6), respectively (P = .07). No difference was seen overall in patients with AKI; however, in those with AKI and hemolysis, creatinine fell by 34.5% (20.7) in the acetaminophen arm vs 25.9% (15.8) in the control arm (P = .041). Mixed-effects modeling demonstrated a benefit of acetaminophen at 72 hours (P = .041) and 1 week (P = .002) in patients with severe malaria and with AKI and hemolysis (P = .027 and P = .002, respectively). CONCLUSIONS: Acetaminophen did not improve creatinine among the entire cohort but may improve renal function in patients with severe knowlesi malaria and in those with AKI and hemolysis. CLINICAL TRIALS REGISTRATION: NCT03056391.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cooper DJ, Grigg MJ, Plewes K, et al. The Effect of Regularly Dosed Acetaminophen vs No Acetaminophen on Renal Function in Plasmodium knowlesi Malaria (PACKNOW): A Randomized, Controlled Trial. Clin Infect Dis. 2022. PMID: 35180298. doi:10.1093/cid/ciac152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。